TeraImmune
Business Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
704 Quince Orchard Rd Ste 160, Gaithersb...Phone Number
(301) 646-8683Website
www.teraimmune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About TeraImmune
TeraImmune, Inc. is a biotechnology company that develops innovative immune-cell therapies. The company's investigational technology programs regulatory T (Treg) cells to recognize and suppress unwanted immune reactions. Increased selectivity of Treg cells with target-specific receptors can enable to suppress the unwanted immune reactions without side effects in the patients with autoimmune diseases. Why are people sick with autoimmune diseases? The body's immune system protects humans from disease and infection. When someone is affected by an autoimmune disease, the immune system attacks healthy cells in the body by mistake. Autoimmune diseases can affect many parts of the body. How can TeraImmune cure the patients with autoimmune diseases?Explore more
TeraImmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TeraImmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at TeraImmune
Check if TeraImmune has recently received funding, and reach out quickly before it becomes old news!
TeraImmune, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if TeraImmune had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once TeraImmune has new funding data
Product Launch: Get notified when TeraImmune launches new products
Earning: See what the market has to say on TeraImmune recently announced quarterly report
Check out if TeraImmune is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to TeraImmune
Compare insights from companies similar to TeraImmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TeraImmune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TeraImmune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TeraImmune.
TeraImmune Tech Stack
A closer look at the technologies used by TeraImmune
TeraImmune News & Media
TeraImmune Extends CRADA for Development of Treg Expansion for Clinical Use
GERMANTOWN, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel regulatory T-cell-(Treg)-based cell therapies for autoimmune diseases, announced today the extension of a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The CRADA is entitled “Developing the process of human regulatory T cells fTeraImmune Presented Research on TREGable™ Technology at HCA Asia 2022
GERMANTOWN, Md., Nov. 18, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on the discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that it presented data on its TREGable™ technology at the Human Cell Atlas Asia (HCA Asia) 2022 Meeting that took place on November 3 – 4 in Bangkok, Thailand.TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors
GERMANTOWN, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) -- TeraImmune, Inc., a biotechnology company focused on discovery and development of novel Treg-based cell therapies for autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence the Company's Phase 1/2a clinical trial to evaluate its lead candidate, TI-168, in congenital Hemophilia A (HA) patients with refractory inhibitors. TI-168 is a next-generation, au
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TeraImmune
Sign Up For FreeTo access detailed company insights
TeraImmune, Inc. is a biotechnology company that develops innovative immune-cell therapies. The company's investigational technology programs regulatory T (Treg) cells to recognize and suppress unwanted immune reactions. Increased selectivity of Treg cells with target-specific receptors can enable to suppress the unwanted immune reactions without s... Read More
